Publicacions en col·laboració amb investigadors/es de Instituto Cajal (36)

2024

  1. ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis

    British Journal of Pharmacology, Vol. 181, Núm. 17, pp. 3263-3281

  2. Early cortical GABAergic interneurons determine the projection patterns of L4 excitatory neurons

    Science Advances, Vol. 10, Núm. 19

  3. Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice

    Brain, Behavior, and Immunity, Vol. 120, pp. 121-140

2023

  1. Programming of neural progenitors of the adult subependymal zone towards a glutamatergic neuron lineage by neurogenin 2

    Stem Cell Reports, Vol. 18, Núm. 12, pp. 2418-2433

2021

  1. Bcl-2-Assisted Reprogramming of Mouse Astrocytes and Human Fibroblasts into Induced Neurons

    Methods in Molecular Biology (Humana Press Inc.), pp. 57-71

2019

  1. Astrocytic p38α MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Synapse-specific regulation revealed at single synapses is concealed when recording multiple synapses

    Frontiers in Cellular Neuroscience, Vol. 11

  2. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

    Journal of Psychiatry and Neuroscience, Vol. 42, Núm. 1, pp. 59-69

2016

  1. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy

    Frontiers in Neuroscience, Vol. 10, Núm. JUN

  2. Activity-dependent switch of gabaergic inhibition into glutamatergic excitation in astrocyte-neuron networks

    eLife, Vol. 5, Núm. DECEMBER2016

  3. Vascular dysfunction in a transgenic model of Alzheimer's disease: Effects of CB1R and CB2R cannabinoid agonists

    Frontiers in Neuroscience, Vol. 10, Núm. SEP

2015

  1. Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke

    European Journal of Medicinal Chemistry, Vol. 101, pp. 604-615

2014

  1. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 80, pp. 543-561

  2. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 2, pp. 235-246

2013

  1. Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: Implications for the pathogenesis of free radical-induced neurodegenerative disorders

    Psychopharmacology, Vol. 230, Núm. 1, pp. 125-135

  2. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

    Journal of Neuroscience, Vol. 33, Núm. 9, pp. 3953-3966

2012

  1. Dopamine D 1 receptor deletion strongly reduces neurotoxic effects of methamphetamine

    Neurobiology of Disease, Vol. 45, Núm. 2, pp. 810-820

2011

  1. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA

    Neurobiology of Disease, Vol. 42, Núm. 3, pp. 391-403

2010

  1. Lack of adrenomedullin, but not complement factor H, results in larger infarct size and more extensive brain damage in a focal ischemia model

    Neuroscience, Vol. 171, Núm. 3, pp. 885-892

  2. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.

    Neurotoxicity research, Vol. 18, Núm. 1, pp. 48-58